DRKS00023348已完成4 期

Acupuncture in chemotherapy-induced dysgeusia – a randomized controlled trial – AcuDysg - AcuDysg

Institut für komplementäre und integrative Medizin UniversitätsSpital Zürich0 个研究点目标入组 22 人开始时间: 2020年11月3日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•indication of supportive routine care acupuncture treatment for fatigue, with a fatigue intensity of at least 3 on a numeric rating scale (NRS 1-10)
•- dysgeusia of at least 5 on NRS (=moderate dysgeusia, NRS 1-10) in the screening tool (adapted from Zabernigg A. et al., 2010)
•- actually treated with a chemotherapy regime that includes taxanes, platinum-based antineoplastic drugs or antrazyclins
•- chemotherapy treatment is planned to continue at least 8 weeks after beginning of acupuncture treatment
•- breast, ovarian, endometrial, pancreas, colorectal, lung, prostate cancer, urothelial carcinoma, germ cell tumor or sarcoma
•- lymphomas with bone marrow infiltration <50% that are under treatment with antrazyclins
•- performance status of ECOG 0-1
•- can eat normal food without pain or swallowing problems
•- internet access and interested to use e-learning

•- currently receive acupuncture treatment
•- dysgeusia that occurred independently of the chemotherapy treatments of the current cancer
•- confirmed positive COVID-19 test with associated dysgeusia prior to chemotherapy treatment
•- increased risk of bleeding e.g. caused by haemophilia or platelets<50000 µl
•- coexisting MDS
•- don’t speak sufficient German
•- mucositis and dysgeusia with an impact on nutrition (pain or swallowing problems)
•- currently receiving or have a planned radiotherapy during the intervention period (within the next 12 weeks) in the head/neck area

发起方

Institut für komplementäre und integrative Medizin UniversitätsSpital Zürich